Pricey or priceless : cost-effectiveness of respiratory syncytial virus (RSV) prevention in infants

Source
The Lancet regional health. Americas - ISSN 2667-193X-29 (2024) p. 1-2

COVID-19-related health utility values and changes in COVID-19 patients and the general population : a scoping review

Source
Quality of life research - ISSN 0962-9343-33:6 (2024) p. 1443-1454
Author(s)

Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022

Source
Vaccine - ISSN 0264-410X-41:48 (2023) p. 7047-7059
Author(s)
    Meagan C. Fitzpatrick, Rachel S. Laufer, Ranju Baral, Amanda J. Driscoll, Daniel R. Feikin, Jessica A. Fleming, Mark Jit, Sonnie Kim, Mihaly Koltai, You Li, Xiao Li, Harish Nair, Kathleen M. Neuzil, Clint Pecenka, Erin Sparrow, Padmini Srikantiah, Justin R. Ortiz

The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries : a semi-parametric, meta-regression approach

Source
PLoS medicine - ISSN 1549-1277-20:7 (2023) p. 1-25
Author(s)

Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection : a multi-country prospective cohort study in Europe

Source
Vaccine - ISSN 0264-410X-41:16 (2023) p. 2707-2715
Author(s)
    Zhuxin Mao, Xiao Li, Ana Dacosta-Urbieta, Marie-Noelle Billard, Joanne Wildenbeest, Koos Korsten, Federico Martinon-Torres, Terho Heikkinen, Steve Cunningham, Matthew D. Snape, Hannah Robinson, Andrew J. Pollard, Maarten Postma, Benoit Dervaux, Niel Hens, Louis Bont, Joke Bilcke, Philippe Beutels